Key result
Packaged GaN HEMT biosensor detects S100B brain injury biomarker in under 15 seconds.
The developed GaN HEMT-based biosensor offers rapid, highly sensitive detection of brain injury biomarkers with good stability, showing potential for real-time clinical application.
May support rapid S100B testing in brain injury; leaves open clinical validation before adoption.
In this Letter, an extended pad packaged GaN HEMT-based biosensing system has been reported for the detection of US Food and Drug Administration-approved ubiquitin-C-terminal-hydrolase-L1 and glial fibrillary acidic protein and Scandinavian Neurotrauma Committee-recommended S100B brain injury biomarkers in clinically relevant concentration ranges. The work is an extension of our preliminary reported work on the noninvasive detection of traumatic brain injury biomarkers using saliva [R. Thakur, IEEE Sens. J. 24(3), 2313 (2023)]. A very high sensitivity of 0.58 mA/ng/ml with good linearity (Adj. R2 = 0.99) was observed for the detection of S100B with a response time of less than 15 s. The platform offers a shelf life of four weeks with minute degradation of −3.08% and −4.66% in its stability and reactivity. The developed biosensing platform shows great potential for its deployment in real-time application areas due to its high sensitivity, good shelf life, and fast detection time.
No takes yet. Share an insight, caveat, or question.
Thakur et al. (2025) conducted a letter in Brain injury. Packaged GaN HEMT-based biosensing system was evaluated on Detection of S100B biomarker. A packaged GaN HEMT-based biosensing system detected the S100B brain injury biomarker with a sensitivity of 0.58 mA/ng/ml and a response time of less than 15 seconds.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: